Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Recent Health Care Deals, week ending 9.11.15
AcquirerTargetPrice Agilent Technologies Inc. Seahorse Bioscience$235 million Concordia Healthcare Corp.Amdipharm Mercury Limited$3.3 billion Eprirus Biopharmaceuticals, Inc. Bioceros Holding B.V.$14.1 million Biogen Inc. License to MT-1303$60 million Apricus Biosciences, Inc. U.S. rights to Vitaros™$1... Read More »Another Priority Review Voucher Sold
In August, AbbVie (NYSE: ABBV) paid a record-setting $350 million to United Therapeutics Corp. (NASDAQ: UTHR) for its Rare Pediatric Disease Priority Review Voucher. The fast-track voucher was awarded by the FDA as part of its approval of Unituxin™ (dintuximab), for the treatment of neuroblastoma. On Sept. 8, the FDA cleared Wellstat Therapeutics’ Xuriden (uridine triacetate) for the treatment of hereditary orotic aciduria, a rare, potentially fatal genetic disorder. It also granted a Rare Pediatric Disease Priority Review Voucher to the privately held Wellstat. That voucher was immediately sold to AstraZeneca (NYSE: AZN) as part of an agreement made in September 2014. Financial... Read More »Personalized Medicine Isn’t All Biotech
There are many sides to personalized medicine, and genetic testing is just one. Another cropped up last week in an acquisition made by Restore Health, a privately held Wisconsin company that provides personalized medicines to health care providers across the United States. Its target was Diplomat Pharmacy’s (NYSE: DPLO) compounding pharmacy business, which includes preparation of personalized medicines for patients, and compounding pharmacists who work with prescribers to customize medication to meet specific patient health needs. The deal frees up Diplomat to focus on its core specialty pharmacy operations, which were bolstered with its acquisition of Burman’s Specialty Pharmacy for $82.8... Read More »Behavioral Health Care M&A in 2015
It’s only mid-September, but the number of behavioral health care transactions is approaching last year’s total—and is likely to surpass it. Through September 11, we’ve recorded 21 deals in this sector, compared with 2014’s total of 22, which was the highest number of deals since 2006’s total of 24 transactions. American Addiction Centers (NYSE: AAC) and Acadia Healthcare Company (NASDAQ: ACHC) made four deals apiece, and six private equity firms, including Flexpoint Ford, Kohlberg and Company and Revelstoke Capital Partners, made one acquisition apiece. YearTotal DealsTotal Dollars 2015*21$474 million 201422$2.2 billion 201318$136 million 201217$1.0 billion 201114$314 million * through... Read More »Telehealth Attracts Big Players
At every healthcare deal making conference we attend, some speaker or moderator inevitably declares, “Telehealth is the wave of the future.” Those observations are coming true, based on the deals we’ve seen in 2015. Last week, Cox Communications, the broadband/cable giant from Georgia, added Trapollo LLC, a privately held nationwide telehealth and remote monitoring company to its growing arsenal of telehealth companies under Vivre Health umbrella. Cox teamed up with Cleveland Clinic earlier this year to form Vivre Health, and invested in HealthSpot, a telehealth technology company that also added Xerox (NYSE: XRX) as an investor last November. Trapollo is wholly owned by Cox, which is... Read More »Recent Health Care Deals, Week Ending Sept. 4, 2015
AcquirerTargetTarget SectorPrice LHC Group, Inc. Halcyon Hospice LLCHome Health & Hospice$58.5 million Allergan plcAqueSys, Inc. Medical Devices$300 million Cilpa Ltd. 2 U.S. generic drug companiesPharmaceuticals$550 million Care Capital Properties 9 senior care propertiesLong-Term Care$190... Read More »Biggest Health Care Deals in August 2015
August 2015 turned out to be busier than usual, for the last month of summer. We counted 124 health care transactions with a combined value of nearly $12 billion. Not bad for the dog days of summer. Five deals disclosed prices of $1 billion or more. Here they are. AcquirerTargetPrice Greatbatch, Inc. Lake Region Medical$1.73 billion Team Health HoldingsIPC Healthcare, Inc. $1.60 billion Mallinckrodt plcTherakos, Inc. $1.32 billion IBM Merge Healthcare$1.0 billion Valeant Pharmaceuticals InternationalSprout Pharmaceuticals$1.0 billion Source: The Health Care M&A Information Source, September 4,... Read More »Valeant Pharmaceuticals Keeps Buying
Valeant Pharmaceuticals International (NYSE: VRX) couldn’t keep its checkbook closed last week. On September 1, Valeant obtained the exclusive license to develop and commercialize brodalumab, a psoriasis drug candidate, from AstraZeneca (NYSE: AZN) for $100 million. Valeant will hold the exclusive rights to develop and commercialize brodalumab globally, except in Japan and certain other Asian countries where rights are held by Kyowa Hakko Kirin Co., Ltd. under a prior arrangement with Amgen Inc. (NASDAQ: AMGN), the originator of brodalumab. A day later, the company announced its acquisition of Synergetics USA, Inc. (NASDAQ: SURG), a medical device company specializing in surgical... Read More »Big Generic Drug Deal for Lannett
The month of September got off to a busy start, with more than 32 acquisitions announced in just the first week. The biggest deal, by disclosed price, was Lannett Company’s (NYSE: LCI) $1.23 billion bid for Kremers Urban Pharmaceuticals, a subsidiary of UCB S.A. (Euronext: UCB). The deal adds near-term growth potential for LCI, with 11 product applications pending at the FDA, five of which include Paragraph IV certifications. Lannett believes the acquisition will be accretive to adjusted EPS in fiscal 2016 in the mid- to high-single digits and 20% to 25% in fiscal 2017. Lannett expects to receive a significant tax benefit as a result of 338(h)(10) election with a value in excess of... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
